ClinicalTrials.gg
Status unknownNCT01547104Updated Apr 11, 2012

Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Linagliptin and Glimepiride in Diabetes Mellitus Type 2, sponsored by Marcus Borchert. Status unknown at 1 site in Germany. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Marcus Borchert · Phase 4, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Apr 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Planned enrollment
53rd of 67
40 · median 175
Started
2012
with 5 others
Phase 4
22 of 67
1 open now
Registered
28th of 67
by date

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 53rd largest by planned enrollment, is one of 6 that started in 2012, is one of 22 in phase 4, and was the 28th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this mechanistic study is to investigate the effect of Linagliptin in comparison to Glimepiride as add on therapy on several parameters characterizing postprandial metabolism and oxidative stress in type 2 diabetic patients on stable control with metformin.

Read the detailed description

The goal of this mechanistic study is to investigate the effect of Linagliptin in comparison to Glimepiride as add on therapy on several parameters characterizing postprandial metabolism and oxidative stress in type 2 diabetic patients on stable control with metformin.

This mechanistic phase IV study has a prospective, comparative, open, randomized, two arm and exploratory design. Overall 40 Patients will be randomized to two treatment arms both receiving Metformin at a maximally tolerated dose. In addition to that both treatment groups will receive either an individually titrated dose of Glimepiride or 5mg once daily of Linagliptin. Subsequent to a standardized meal, several parameters reflecting beta cell function, metabolism and oxidative stress will be evaluated.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diabetes mellitus type 2
  2. > 6.5% - ≤ 8.5%
  3. HbA1c > 7.0% - ≤ 8.5% for those patients with a significant cardiovascular history
  4. Treatment with metformin at a maximum tolerated dose
  5. Age 45 - 75 years (inclusively)
  6. Patient consents that his/her family physician/diabetologist will be informed of trial participation.

Exclusion criteria

Exclusion Criteria:

  1. Pretreatment with PPAR gamma agonists within the last three months
  2. History of type 1 diabetes
  3. Uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg)
  4. Acute infections
  5. Medical history of to the study drugs or to drugs with similar chemical structures
  6. History of severe or multiple allergies
  7. Treatment with any other drug within 3 months before trial entry.
  8. Progressive fatal disease
  9. History of drug or alcohol abuse in the past 2 years
  10. State after kidney transplantation
  11. Serum potassium > 5.5 mmol/L
  12. Pregnancy or breast feeding
  13. Sexually active woman of childbearing age not practicing a highly effective method of as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomized partner.
  14. Acute myocardial infarction, open heart surgery or cerebral event (stroke/) within the previous 30 days
  15. Any elective surgery during study participation
  16. Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit
  17. History of pancreatitis
  18. History of dehydration, pre-coma diabeticum or diabetic ketoacidosis
  19. Acute or scheduled investigation with iodine containing radiopaque material
  20. Uncontrolled unstable angina pectoris
  21. History of pericarditis, myocarditis, endocarditis
  22. Recent pulmonary embolism
  23. Hemodynamic relevant aortic stenosis
  24. Aortic aneurysm
  25. Regular use of NSAID's (no acute use of NSAID within 48 hours before V2,V4,V5)
  26. Lack of compliance or other similar reason that, according to investigator, precludes satisfactory participation in the study
  27. History of respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (Creatinine > 1.1 mg/dl in women and > 1.5 mg/dl in men ), neurological, psychiatric and/or hematological disease as judged by the investigator
  28. Lactose intolerance
  29. Intake of Coumarin or coumarin derived compounds such as phenprocoumon (Marcumar) or warfarin (Coumadin, Warfant)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Glimepiride-ratiopharm

    Glimepiride (1-4mg) as add on therapy

    Drug: Glimepiride

  • Experimental
    Trajenta

    Linagliptin 5 mg as add on therapy

    Drug: Linagliptin

Interventions

  • Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy

  • Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy

    Also known as: Glimepirid-ratiopharm

06

What researchers measure

Primary outcomes

  1. Postprandial increase in intact Proinsulin levels (Peak, AUC)

    Time frame: 30, 60, 90, 120, 150, 180, 210, 240, 270 300 mins post test meal procedure, 3 times within 12 weeks treatment

  2. Postprandial Proinsulin/Insulin Ratio

    Time frame: after 12 weeks treatment

  3. Fasting intact Proinsulin levels

    Time frame: after 12 weeks treatment

  4. Fasting Proinsulin/Insulin Ratio

    Time frame: after 12 weeks treatment

  5. Fasting Blood Glucose

    Time frame: after 12 weeks treatment

  6. Postprandial Blood Glucose Excursions (Peak; AUC)

    Time frame: 30, 60, 90, 120, 150, 180, 210, 240, 270 300 mins post test meal procedure, 3 times within 12 weeks treatment

  7. Fasting Lipids

    Time frame: after 12 weeks treatment

  8. Postprandial Lipids

    Time frame: after 12 weeks treatment

  9. Fasting Erythrocyte Flexibility

    Time frame: after 12 weeks treatment

  10. Postprandial Erythrocyte Flexibility

    Time frame: after 12 weeks treatment

  11. Fasting GLP-1 levels

    Time frame: after 12 weeks treatment

  12. Postprandial GLP-1 levels

    Time frame: after 12 weeks treatment

  13. Fasting cGMP

    Time frame: after 12 weeks treatment

  14. Postprandial cGMP

    Time frame: after 12 weeks treatment

  15. Fasting Calcitonin

    Time frame: after 12 weeks treatment

  16. Fasting PAI-1 levels

    Time frame: after 12 weeks treatment

  17. Postprandial PAI-1 levels

    Time frame: after 12 weeks treatment

  18. Fasting ADMA levels

    Time frame: after 12 weeks treatment

  19. Postprandial ADMA levels

    Time frame: after 12 weeks treatment

  20. Fasting Malonyldialdehyd

    Time frame: after 12 weeks treatment

  21. fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo

    Time frame: after 12 weeks treatment

Secondary outcomes

  1. Hypoglycemic events

    Time frame: after 12 weeks treatment

  2. Body Weight

    Time frame: after 12 weeks treatment

07

Study locations

1 of 1 sites recruiting
  • ikfe GmbH
    Mainz, Rhineland-Palatinate 55116, Germany
    Recruiting
    • Thomas Forst, MD, PhD · ContactThomasF@ikfe.de · + 49 6131 57636
    • Daniela Sachsenheimer, MD · ContactDanielaS@ikfe.de · + 49 6131 57636
    • Daniela Sachsenheimer, MD · Sub investigator
    • Stephanie Helleberg, MD · Sub investigator
    • Stefan Diessel · Sub investigator
    • Michael Mitry, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2012
First posted
Mar 7, 2012
Start
Apr 2012
Primary completionEst.
Oct 2012
CompletionEst.
Oct 2012
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01547104
Lead sponsor
Marcus Borchert
Collaborators
ikfe-CRO GmbH, Boehringer Ingelheim
Responsible party
Marcus Borchert (Prof. Dr. Thomas Forst, ikfe-CRO GmbH) — Sponsor-investigator
First posted
Mar 7, 2012
Start date
Apr 2012
Primary completion
Oct 2012 (estimated)
Completion
Oct 2012 (estimated)
Last update
Apr 11, 2012

Study contacts

Thomas Forst, MD, PhD
Contact
ThomasF@ikfe.de
+ 49 6131 57636 ext. 16
Claudia Forkel
Contact
C.Forkel@ikfe-cro.de
+ 49 6131 32790 ext. 32
Thomas Forst, MD, PhD
principal investigator · Ikfe GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion